<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953328</url>
  </required_header>
  <id_info>
    <org_study_id>20120122</org_study_id>
    <nct_id>NCT01953328</nct_id>
  </id_info>
  <brief_title>Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk</brief_title>
  <acronym>AMG145</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous
      evolocumab administered every 2 weeks and once a month, compared with placebo, on percent
      change from baseline in LDL-C when used in combination with statin therapy in adults with
      high cardiovascular risk and with hyperlipidemia or mixed dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a screening and placebo run-in period, eligible patients were randomized in a 1:1 ratio
      to 1 of 2 open-label background statin treatments (atorvastatin 5 mg or 20 mg daily [QD]) and
      entered a 4-week lipid stabilization period. After the lipid stabilization period, eligible
      patients were randomized in a 1:1:1:1 ratio to investigational product (evolocumab or
      placebo) for the 12-week treatment period.

      Both randomizations were stratified by subject diagnosis and lipid-lowering therapy as
      follows:

        -  current or prior diagnosis of heterozygous familial hypercholesterolemia (HeFH)

        -  no diagnosis of HeFH and receiving intensive lipid-lowering therapy

        -  no diagnosis of HeFH and receiving non-intensive lipid-lowering therapy. A participant
           was considered randomized into the study after successfully completing the screening
           period, meeting all inclusion/exclusion criteria including meeting final laboratory
           safety criteria, and undergoing both randomization procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</measure>
    <time_frame>Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in VLDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>A5 Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A5 Placebo QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A5 Evolocumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A5 Evolocumab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A20 Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A20 Placebo QM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A20 Evolocumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A20 Evolocumab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>A5 Placebo Q2W</arm_group_label>
    <arm_group_label>A5 Placebo QM</arm_group_label>
    <arm_group_label>A5 Evolocumab Q2W</arm_group_label>
    <arm_group_label>A5 Evolocumab QM</arm_group_label>
    <arm_group_label>A20 Placebo Q2W</arm_group_label>
    <arm_group_label>A20 Placebo QM</arm_group_label>
    <arm_group_label>A20 Evolocumab Q2W</arm_group_label>
    <arm_group_label>A20 Evolocumab QM</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>A5 Evolocumab Q2W</arm_group_label>
    <arm_group_label>A5 Evolocumab QM</arm_group_label>
    <arm_group_label>A20 Evolocumab Q2W</arm_group_label>
    <arm_group_label>A20 Evolocumab QM</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>A5 Placebo Q2W</arm_group_label>
    <arm_group_label>A5 Placebo QM</arm_group_label>
    <arm_group_label>A20 Placebo Q2W</arm_group_label>
    <arm_group_label>A20 Placebo QM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Male or female, Japanese adult, 20-85 years of age; Subjects on stable
        dose of statin for greater than equal to 4 weeks; Fasting LDL-C greater than equal to 100
        mg/dL; Fasting triglycerides less than equal to 400 mg/dL; Subject is at high risk for
        cardiovascular events. Exclusion Criteria: New York heart Association (NYHA) III or IV -
        heart failure; Uncontrolled cardiac arrhythmia; Uncontrolled hypertension; Type 1 diabetes,
        poorly controlled type 2 diabetes; Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akita-shi</city>
        <state>Akita</state>
        <zip>010-1423</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Noda-shi</city>
        <state>Chiba</state>
        <zip>278-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>819-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyusyu-shi</city>
        <state>Fukuoka</state>
        <zip>807-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-0209</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8862</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <zip>370-3524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsuchiura-shi</city>
        <state>Ibaraki</state>
        <zip>300-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanamaki-shi</city>
        <state>Iwate</state>
        <zip>025-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <zip>760-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <zip>760-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>615-8125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>983-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>983-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>989-3122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomigusuku-shi</city>
        <state>Okinawa</state>
        <zip>901-0243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urasoe-shi</city>
        <state>Okinawa</state>
        <zip>901-2132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibaraki-shi</city>
        <state>Osaka</state>
        <zip>567-0876</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama</state>
        <zip>343-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumagaya-shi</city>
        <state>Saitama</state>
        <zip>360-0816</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niiza-shi</city>
        <state>Saitama</state>
        <zip>352-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <zip>116-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chofu-shi</city>
        <state>Tokyo</state>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>124-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>144-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>155-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-6003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <results_first_submitted>September 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2015</results_first_posted>
  <disposition_first_submitted>April 9, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 1, 2015</disposition_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese, high cholesterol, LDL-C, High Cardiovascular Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Japanese men and women ≥ 20 to ≤ 85 years of age, with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (2.6 mmol/L), fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L), and at high risk for cardiovascular events were eligible to participate. First patient enrolled on 07 October 2013 and last patient enrolled on 17 February 2014.</recruitment_details>
      <pre_assignment_details>409 participants were randomized to 1 of 2 open-label atorvastatin cohorts (5 mg or 20 mg) for the lipid stabilization period; 404 were then randomized to blinded investigational product. Both randomizations were stratified by heterozygous familial hypercholesterolemia (HeFH) diagnosis and lipid-lowering therapy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A5 Placebo Q2W</title>
          <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>A5 Placebo QM</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>A5 Evolocumab Q2W</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>A5 Evolocumab QM</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>A20 Placebo Q2W</title>
          <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>A20 Placebo QM</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>A20 Evolocumab Q2W</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>A20 Evolocumab QM</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="51"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="51"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="51"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (all randomized participants who reveid at least 1 dose of blinded investigational product).</population>
      <group_list>
        <group group_id="B1">
          <title>A5 Placebo Q2W</title>
          <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>A5 Placebo QM</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>A5 Evolocumab Q2W</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>A5 Evolocumab QM</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>A20 Placebo Q2W</title>
          <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>A20 Placebo QM</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>A20 Evolocumab Q2W</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>A20 Evolocumab QM</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="51"/>
            <count group_id="B7" value="51"/>
            <count group_id="B8" value="51"/>
            <count group_id="B9" value="404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="9.9"/>
                    <measurement group_id="B2" value="60.6" spread="9.9"/>
                    <measurement group_id="B3" value="65.2" spread="7.8"/>
                    <measurement group_id="B4" value="60.1" spread="11.6"/>
                    <measurement group_id="B5" value="60.4" spread="10.4"/>
                    <measurement group_id="B6" value="60.4" spread="10.5"/>
                    <measurement group_id="B7" value="60.1" spread="9.9"/>
                    <measurement group_id="B8" value="61.8" spread="11.9"/>
                    <measurement group_id="B9" value="61.3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="51"/>
                    <measurement group_id="B9" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor</title>
          <description>Intensive statin use was defined as daily atorvastatin ≥ 10 mg, fluvastatin ≥ 80 mg, lovastatin ≥ 40 mg, pitavastatin ≥ 2 mg, pravastatin ≥ 40 mg, rosuvastatin ≥ 5 mg, simvastatin ≥ 20 mg, or any statin plus ezetimibe. Non-intensive is defined as any dose of a statin at least weekly for the last 4 weeks prior to screening and not included in the above.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diagnosis of HeFH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HeFH and Intensive Statin Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HeFH and Non-Intensive Statin Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C Concentration</title>
          <description>Baseline lipid parameters were measured after the lipid-stabilization period and prior to administration of first dose of investigational study drug.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115.7" spread="26.0"/>
                    <measurement group_id="B2" value="114.0" spread="29.2"/>
                    <measurement group_id="B3" value="121.9" spread="44.6"/>
                    <measurement group_id="B4" value="118.8" spread="36.6"/>
                    <measurement group_id="B5" value="90.9" spread="25.5"/>
                    <measurement group_id="B6" value="90.7" spread="20.8"/>
                    <measurement group_id="B7" value="95.8" spread="23.6"/>
                    <measurement group_id="B8" value="98.0" spread="25.6"/>
                    <measurement group_id="B9" value="105.5" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142.0" spread="30.4"/>
                    <measurement group_id="B2" value="141.2" spread="31.8"/>
                    <measurement group_id="B3" value="151.8" spread="48.8"/>
                    <measurement group_id="B4" value="147.8" spread="39.6"/>
                    <measurement group_id="B5" value="118.2" spread="28.6"/>
                    <measurement group_id="B6" value="117.5" spread="25.1"/>
                    <measurement group_id="B7" value="121.8" spread="29.8"/>
                    <measurement group_id="B8" value="122.7" spread="29.5"/>
                    <measurement group_id="B9" value="132.7" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.0" spread="20.0"/>
                    <measurement group_id="B2" value="100.6" spread="20.0"/>
                    <measurement group_id="B3" value="105.1" spread="31.2"/>
                    <measurement group_id="B4" value="102.2" spread="24.7"/>
                    <measurement group_id="B5" value="85.7" spread="18.4"/>
                    <measurement group_id="B6" value="82.7" spread="14.6"/>
                    <measurement group_id="B7" value="87.2" spread="19.1"/>
                    <measurement group_id="B8" value="87.7" spread="19.6"/>
                    <measurement group_id="B9" value="93.7" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199.5" spread="30.7"/>
                    <measurement group_id="B2" value="199.4" spread="33.2"/>
                    <measurement group_id="B3" value="210.4" spread="47.9"/>
                    <measurement group_id="B4" value="202.5" spread="38.4"/>
                    <measurement group_id="B5" value="177.8" spread="33.0"/>
                    <measurement group_id="B6" value="173.6" spread="29.2"/>
                    <measurement group_id="B7" value="177.7" spread="26.2"/>
                    <measurement group_id="B8" value="179.0" spread="29.4"/>
                    <measurement group_id="B9" value="189.8" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/HDL-C Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.618" spread="0.891"/>
                    <measurement group_id="B2" value="3.579" spread="0.827"/>
                    <measurement group_id="B3" value="3.743" spread="1.186"/>
                    <measurement group_id="B4" value="3.933" spread="1.295"/>
                    <measurement group_id="B5" value="3.116" spread="0.760"/>
                    <measurement group_id="B6" value="3.170" spread="0.612"/>
                    <measurement group_id="B7" value="3.392" spread="1.112"/>
                    <measurement group_id="B8" value="3.400" spread="1.071"/>
                    <measurement group_id="B9" value="3.491" spread="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.633" spread="0.160"/>
                    <measurement group_id="B2" value="0.628" spread="0.152"/>
                    <measurement group_id="B3" value="0.643" spread="0.223"/>
                    <measurement group_id="B4" value="0.658" spread="0.235"/>
                    <measurement group_id="B5" value="0.529" spread="0.118"/>
                    <measurement group_id="B6" value="0.524" spread="0.108"/>
                    <measurement group_id="B7" value="0.575" spread="0.177"/>
                    <measurement group_id="B8" value="0.576" spread="0.176"/>
                    <measurement group_id="B9" value="0.595" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein(a) Concentration</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" lower_limit="16.5" upper_limit="52.5"/>
                    <measurement group_id="B2" value="29.5" lower_limit="9.0" upper_limit="47.0"/>
                    <measurement group_id="B3" value="36.0" lower_limit="16.0" upper_limit="69.0"/>
                    <measurement group_id="B4" value="36.5" lower_limit="16.0" upper_limit="74.0"/>
                    <measurement group_id="B5" value="30.0" lower_limit="11.0" upper_limit="45.0"/>
                    <measurement group_id="B6" value="35.0" lower_limit="11.0" upper_limit="57.0"/>
                    <measurement group_id="B7" value="33.0" lower_limit="14.0" upper_limit="49.0"/>
                    <measurement group_id="B8" value="28.0" lower_limit="11.0" upper_limit="60.0"/>
                    <measurement group_id="B9" value="33.0" lower_limit="13.0" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride Concentration</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.0" lower_limit="90.0" upper_limit="174.0"/>
                    <measurement group_id="B2" value="128.5" lower_limit="99.0" upper_limit="164.0"/>
                    <measurement group_id="B3" value="125.0" lower_limit="97.0" upper_limit="172.0"/>
                    <measurement group_id="B4" value="132.0" lower_limit="103.0" upper_limit="171.0"/>
                    <measurement group_id="B5" value="120.0" lower_limit="91.5" upper_limit="187.0"/>
                    <measurement group_id="B6" value="120.0" lower_limit="87.0" upper_limit="154.0"/>
                    <measurement group_id="B7" value="109.0" lower_limit="82.0" upper_limit="149.0"/>
                    <measurement group_id="B8" value="113.0" lower_limit="95.0" upper_limit="137.0"/>
                    <measurement group_id="B9" value="121.5" lower_limit="92.0" upper_limit="161.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-C Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="13.6"/>
                    <measurement group_id="B2" value="58.3" spread="14.6"/>
                    <measurement group_id="B3" value="58.6" spread="12.7"/>
                    <measurement group_id="B4" value="54.7" spread="13.9"/>
                    <measurement group_id="B5" value="59.6" spread="15.4"/>
                    <measurement group_id="B6" value="56.0" spread="11.3"/>
                    <measurement group_id="B7" value="55.9" spread="14.4"/>
                    <measurement group_id="B8" value="56.3" spread="15.7"/>
                    <measurement group_id="B9" value="57.1" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very-Low-Density Lipoprotein Cholesterol (VLDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="11.0"/>
                    <measurement group_id="B2" value="26.8" spread="10.2"/>
                    <measurement group_id="B3" value="29.2" spread="14.7"/>
                    <measurement group_id="B4" value="29.0" spread="12.8"/>
                    <measurement group_id="B5" value="27.4" spread="12.0"/>
                    <measurement group_id="B6" value="25.1" spread="9.4"/>
                    <measurement group_id="B7" value="24.3" spread="10.7"/>
                    <measurement group_id="B8" value="24.7" spread="10.3"/>
                    <measurement group_id="B9" value="26.6" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="2.21"/>
                    <measurement group_id="O2" value="3.91" spread="2.09"/>
                    <measurement group_id="O3" value="-73.70" spread="2.26"/>
                    <measurement group_id="O4" value="-69.98" spread="2.02"/>
                    <measurement group_id="O5" value="-0.42" spread="3.26"/>
                    <measurement group_id="O6" value="-2.67" spread="2.31"/>
                    <measurement group_id="O7" value="-74.82" spread="3.26"/>
                    <measurement group_id="O8" value="-76.93" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-73.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.54</ci_lower_limit>
            <ci_upper_limit>-69.41</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-72.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.22</ci_lower_limit>
            <ci_upper_limit>-68.57</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-74.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-81.21</ci_lower_limit>
            <ci_upper_limit>-67.61</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-74.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.93</ci_lower_limit>
            <ci_upper_limit>-69.60</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="2.43"/>
                    <measurement group_id="O2" value="5.29" spread="2.19"/>
                    <measurement group_id="O3" value="-73.57" spread="2.48"/>
                    <measurement group_id="O4" value="-64.62" spread="2.12"/>
                    <measurement group_id="O5" value="1.39" spread="3.51"/>
                    <measurement group_id="O6" value="-3.49" spread="2.67"/>
                    <measurement group_id="O7" value="-74.46" spread="3.50"/>
                    <measurement group_id="O8" value="-70.36" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-74.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-80.22</ci_lower_limit>
            <ci_upper_limit>-69.47</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-69.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.60</ci_lower_limit>
            <ci_upper_limit>-65.23</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-78.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.55</ci_lower_limit>
            <ci_upper_limit>-68.15</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.88</ci_lower_limit>
            <ci_upper_limit>-60.87</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="4.3"/>
                    <measurement group_id="O2" value="-2.6" spread="4.3"/>
                    <measurement group_id="O3" value="-104.1" spread="4.4"/>
                    <measurement group_id="O4" value="-88.9" spread="4.1"/>
                    <measurement group_id="O5" value="-8.9" spread="3.2"/>
                    <measurement group_id="O6" value="-5.7" spread="3.7"/>
                    <measurement group_id="O7" value="-77.6" spread="3.2"/>
                    <measurement group_id="O8" value="-77.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-89.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-98.4</ci_lower_limit>
            <ci_upper_limit>-80.2</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-86.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-95.1</ci_lower_limit>
            <ci_upper_limit>-77.5</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.3</ci_lower_limit>
            <ci_upper_limit>-62.1</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-72.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.5</ci_lower_limit>
            <ci_upper_limit>-64.6</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="4.6"/>
                    <measurement group_id="O2" value="-0.4" spread="4.3"/>
                    <measurement group_id="O3" value="-104.5" spread="4.6"/>
                    <measurement group_id="O4" value="-84.0" spread="4.2"/>
                    <measurement group_id="O5" value="-7.7" spread="3.3"/>
                    <measurement group_id="O6" value="-6.2" spread="4.0"/>
                    <measurement group_id="O7" value="-77.2" spread="3.3"/>
                    <measurement group_id="O8" value="-71.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-90.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-100.9</ci_lower_limit>
            <ci_upper_limit>-80.7</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-83.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-92.5</ci_lower_limit>
            <ci_upper_limit>-74.8</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-69.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.5</ci_lower_limit>
            <ci_upper_limit>-62.6</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.8</ci_lower_limit>
            <ci_upper_limit>-57.1</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="2.13"/>
                    <measurement group_id="O2" value="4.26" spread="1.86"/>
                    <measurement group_id="O3" value="-68.48" spread="2.18"/>
                    <measurement group_id="O4" value="-61.69" spread="1.80"/>
                    <measurement group_id="O5" value="-1.57" spread="2.45"/>
                    <measurement group_id="O6" value="-1.79" spread="1.94"/>
                    <measurement group_id="O7" value="-69.72" spread="2.45"/>
                    <measurement group_id="O8" value="-69.07" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.06</ci_lower_limit>
            <ci_upper_limit>-64.27</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.74</ci_lower_limit>
            <ci_upper_limit>-62.16</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.30</ci_lower_limit>
            <ci_upper_limit>-62.99</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-67.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.14</ci_lower_limit>
            <ci_upper_limit>-63.42</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="2.30"/>
                    <measurement group_id="O2" value="5.55" spread="2.02"/>
                    <measurement group_id="O3" value="-67.81" spread="2.35"/>
                    <measurement group_id="O4" value="-58.03" spread="1.96"/>
                    <measurement group_id="O5" value="-0.07" spread="2.68"/>
                    <measurement group_id="O6" value="-2.38" spread="2.22"/>
                    <measurement group_id="O7" value="-68.89" spread="2.67"/>
                    <measurement group_id="O8" value="-63.27" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.96</ci_lower_limit>
            <ci_upper_limit>-63.89</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.96</ci_lower_limit>
            <ci_upper_limit>-59.21</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.79</ci_lower_limit>
            <ci_upper_limit>-62.86</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.78</ci_lower_limit>
            <ci_upper_limit>-55.99</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="1.98"/>
                    <measurement group_id="O2" value="0.76" spread="2.06"/>
                    <measurement group_id="O3" value="-64.76" spread="2.03"/>
                    <measurement group_id="O4" value="-58.47" spread="1.99"/>
                    <measurement group_id="O5" value="-4.32" spread="2.27"/>
                    <measurement group_id="O6" value="-0.85" spread="1.90"/>
                    <measurement group_id="O7" value="-64.38" spread="2.27"/>
                    <measurement group_id="O8" value="-64.24" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-64.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.49</ci_lower_limit>
            <ci_upper_limit>-60.39</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.30</ci_lower_limit>
            <ci_upper_limit>-55.17</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.87</ci_lower_limit>
            <ci_upper_limit>-55.25</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.15</ci_lower_limit>
            <ci_upper_limit>-59.62</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="2.17"/>
                    <measurement group_id="O2" value="2.42" spread="2.26"/>
                    <measurement group_id="O3" value="-64.83" spread="2.22"/>
                    <measurement group_id="O4" value="-54.80" spread="2.19"/>
                    <measurement group_id="O5" value="-2.47" spread="2.48"/>
                    <measurement group_id="O6" value="-1.89" spread="2.17"/>
                    <measurement group_id="O7" value="-62.83" spread="2.47"/>
                    <measurement group_id="O8" value="-58.04" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.34</ci_lower_limit>
            <ci_upper_limit>-60.79</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.05</ci_lower_limit>
            <ci_upper_limit>-52.40</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.91</ci_lower_limit>
            <ci_upper_limit>-54.83</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.92</ci_lower_limit>
            <ci_upper_limit>-51.39</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="1.81"/>
                    <measurement group_id="O2" value="1.09" spread="1.63"/>
                    <measurement group_id="O3" value="-48.03" spread="1.85"/>
                    <measurement group_id="O4" value="-42.34" spread="1.58"/>
                    <measurement group_id="O5" value="-4.21" spread="1.86"/>
                    <measurement group_id="O6" value="-2.35" spread="1.68"/>
                    <measurement group_id="O7" value="-45.19" spread="1.86"/>
                    <measurement group_id="O8" value="-45.49" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.35</ci_lower_limit>
            <ci_upper_limit>-41.73</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.78</ci_lower_limit>
            <ci_upper_limit>-40.08</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.88</ci_lower_limit>
            <ci_upper_limit>-37.08</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.48</ci_lower_limit>
            <ci_upper_limit>-39.80</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="1.97"/>
                    <measurement group_id="O2" value="2.29" spread="1.67"/>
                    <measurement group_id="O3" value="-47.14" spread="2.01"/>
                    <measurement group_id="O4" value="-39.06" spread="1.62"/>
                    <measurement group_id="O5" value="-3.08" spread="2.00"/>
                    <measurement group_id="O6" value="-2.44" spread="1.81"/>
                    <measurement group_id="O7" value="-44.04" spread="1.99"/>
                    <measurement group_id="O8" value="-40.88" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.83</ci_lower_limit>
            <ci_upper_limit>-41.05</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.84</ci_lower_limit>
            <ci_upper_limit>-37.85</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.35</ci_lower_limit>
            <ci_upper_limit>-36.57</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.26</ci_lower_limit>
            <ci_upper_limit>-34.62</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="2.11"/>
                    <measurement group_id="O2" value="3.94" spread="2.16"/>
                    <measurement group_id="O3" value="-51.00" spread="2.16"/>
                    <measurement group_id="O4" value="-48.71" spread="2.09"/>
                    <measurement group_id="O5" value="1.04" spread="1.82"/>
                    <measurement group_id="O6" value="1.58" spread="2.04"/>
                    <measurement group_id="O7" value="-49.79" spread="1.81"/>
                    <measurement group_id="O8" value="-48.11" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.37</ci_lower_limit>
            <ci_upper_limit>-50.17</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.95</ci_lower_limit>
            <ci_upper_limit>-48.36</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.72</ci_lower_limit>
            <ci_upper_limit>-46.93</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.74</ci_lower_limit>
            <ci_upper_limit>-45.64</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="2.36"/>
                    <measurement group_id="O2" value="4.33" spread="2.33"/>
                    <measurement group_id="O3" value="-50.72" spread="2.40"/>
                    <measurement group_id="O4" value="-46.62" spread="2.26"/>
                    <measurement group_id="O5" value="1.84" spread="2.01"/>
                    <measurement group_id="O6" value="0.83" spread="2.20"/>
                    <measurement group_id="O7" value="-49.52" spread="2.00"/>
                    <measurement group_id="O8" value="-44.61" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.93</ci_lower_limit>
            <ci_upper_limit>-49.98</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.91</ci_lower_limit>
            <ci_upper_limit>-46.00</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-51.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.93</ci_lower_limit>
            <ci_upper_limit>-46.80</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.08</ci_lower_limit>
            <ci_upper_limit>-40.81</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="2.02"/>
                    <measurement group_id="O2" value="2.79" spread="2.37"/>
                    <measurement group_id="O3" value="-66.41" spread="2.07"/>
                    <measurement group_id="O4" value="-61.55" spread="2.29"/>
                    <measurement group_id="O5" value="-1.92" spread="2.30"/>
                    <measurement group_id="O6" value="1.54" spread="2.09"/>
                    <measurement group_id="O7" value="-65.97" spread="2.30"/>
                    <measurement group_id="O8" value="-65.72" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.58</ci_lower_limit>
            <ci_upper_limit>-62.36</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-64.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.01</ci_lower_limit>
            <ci_upper_limit>-59.66</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-64.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.90</ci_lower_limit>
            <ci_upper_limit>-59.20</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-67.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.36</ci_lower_limit>
            <ci_upper_limit>-63.15</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="2.11"/>
                    <measurement group_id="O2" value="4.08" spread="2.62"/>
                    <measurement group_id="O3" value="-67.59" spread="2.16"/>
                    <measurement group_id="O4" value="-58.45" spread="2.53"/>
                    <measurement group_id="O5" value="-1.15" spread="2.47"/>
                    <measurement group_id="O6" value="0.06" spread="2.30"/>
                    <measurement group_id="O7" value="-65.11" spread="2.46"/>
                    <measurement group_id="O8" value="-60.56" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.75</ci_lower_limit>
            <ci_upper_limit>-63.84</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.11</ci_lower_limit>
            <ci_upper_limit>-56.94</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.44</ci_lower_limit>
            <ci_upper_limit>-58.50</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.51</ci_lower_limit>
            <ci_upper_limit>-55.72</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</title>
        <time_frame>Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.02" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" spread="2.37" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O3" value="98.0" spread="2.07" lower_limit="89.5" upper_limit="99.6"/>
                    <measurement group_id="O4" value="96.0" spread="2.29" lower_limit="86.5" upper_limit="98.9"/>
                    <measurement group_id="O5" value="22.4" spread="2.30" lower_limit="13.0" upper_limit="35.9"/>
                    <measurement group_id="O6" value="15.7" spread="2.09" lower_limit="8.2" upper_limit="28.0"/>
                    <measurement group_id="O7" value="96.0" spread="2.30" lower_limit="86.5" upper_limit="98.9"/>
                    <measurement group_id="O8" value="98.0" spread="2.02" lower_limit="89.7" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>98.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.8</ci_lower_limit>
            <ci_upper_limit>99.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>96.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.1</ci_lower_limit>
            <ci_upper_limit>98.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>73.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>57.1</ci_lower_limit>
            <ci_upper_limit>83.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>82.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.5</ci_lower_limit>
            <ci_upper_limit>90.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.02" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="4.2" spread="2.37" lower_limit="1.2" upper_limit="14.0"/>
                    <measurement group_id="O3" value="98.0" spread="2.07" lower_limit="89.3" upper_limit="99.6"/>
                    <measurement group_id="O4" value="96.0" spread="2.29" lower_limit="86.5" upper_limit="98.9"/>
                    <measurement group_id="O5" value="20.4" spread="2.30" lower_limit="11.5" upper_limit="33.6"/>
                    <measurement group_id="O6" value="20.0" spread="2.09" lower_limit="11.2" upper_limit="33.0"/>
                    <measurement group_id="O7" value="96.0" spread="2.30" lower_limit="86.5" upper_limit="98.9"/>
                    <measurement group_id="O8" value="98.0" spread="2.02" lower_limit="89.7" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>98.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.7</ci_lower_limit>
            <ci_upper_limit>99.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>91.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.2</ci_lower_limit>
            <ci_upper_limit>96.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>75.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.3</ci_lower_limit>
            <ci_upper_limit>85.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factor (HeFH diagnosis and lipid-lowering therapy).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>78.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.6</ci_lower_limit>
            <ci_upper_limit>86.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="6.18"/>
                    <measurement group_id="O2" value="4.07" spread="4.95"/>
                    <measurement group_id="O3" value="-45.97" spread="6.27"/>
                    <measurement group_id="O4" value="-45.01" spread="4.78"/>
                    <measurement group_id="O5" value="6.52" spread="4.81"/>
                    <measurement group_id="O6" value="-5.62" spread="5.00"/>
                    <measurement group_id="O7" value="-43.03" spread="4.81"/>
                    <measurement group_id="O8" value="-49.55" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-51.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.88</ci_lower_limit>
            <ci_upper_limit>-38.52</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.89</ci_lower_limit>
            <ci_upper_limit>-39.27</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.74</ci_lower_limit>
            <ci_upper_limit>-39.35</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.75</ci_lower_limit>
            <ci_upper_limit>-34.12</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="6.86"/>
                    <measurement group_id="O2" value="7.03" spread="5.47"/>
                    <measurement group_id="O3" value="-45.72" spread="6.93"/>
                    <measurement group_id="O4" value="-41.74" spread="5.29"/>
                    <measurement group_id="O5" value="10.75" spread="5.15"/>
                    <measurement group_id="O6" value="-5.73" spread="5.18"/>
                    <measurement group_id="O7" value="-41.93" spread="5.13"/>
                    <measurement group_id="O8" value="-45.70" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.25</ci_lower_limit>
            <ci_upper_limit>-34.90</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-48.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.49</ci_lower_limit>
            <ci_upper_limit>-37.05</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.06</ci_lower_limit>
            <ci_upper_limit>-41.30</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.46</ci_lower_limit>
            <ci_upper_limit>-29.48</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="6.04"/>
                    <measurement group_id="O2" value="4.54" spread="5.31"/>
                    <measurement group_id="O3" value="-23.23" spread="6.15"/>
                    <measurement group_id="O4" value="-17.41" spread="5.14"/>
                    <measurement group_id="O5" value="-2.11" spread="4.45"/>
                    <measurement group_id="O6" value="8.06" spread="6.16"/>
                    <measurement group_id="O7" value="-22.12" spread="4.44"/>
                    <measurement group_id="O8" value="-12.66" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.27</ci_lower_limit>
            <ci_upper_limit>-14.59</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-21.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.54</ci_lower_limit>
            <ci_upper_limit>-11.35</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.59</ci_lower_limit>
            <ci_upper_limit>-10.43</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.18</ci_lower_limit>
            <ci_upper_limit>-7.26</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="7.65"/>
                    <measurement group_id="O2" value="4.34" spread="5.61"/>
                    <measurement group_id="O3" value="-19.73" spread="7.74"/>
                    <measurement group_id="O4" value="-15.63" spread="5.43"/>
                    <measurement group_id="O5" value="-3.88" spread="4.85"/>
                    <measurement group_id="O6" value="7.30" spread="6.42"/>
                    <measurement group_id="O7" value="-21.05" spread="4.82"/>
                    <measurement group_id="O8" value="-9.63" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.33</ci_lower_limit>
            <ci_upper_limit>-8.81</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-19.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.68</ci_lower_limit>
            <ci_upper_limit>-8.25</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-17.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.15</ci_lower_limit>
            <ci_upper_limit>-6.19</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.29</ci_lower_limit>
            <ci_upper_limit>-2.56</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.83" spread="2.25"/>
                    <measurement group_id="O2" value="-1.57" spread="2.29"/>
                    <measurement group_id="O3" value="7.50" spread="2.30"/>
                    <measurement group_id="O4" value="13.05" spread="2.22"/>
                    <measurement group_id="O5" value="-4.03" spread="2.34"/>
                    <measurement group_id="O6" value="-3.06" spread="2.13"/>
                    <measurement group_id="O7" value="11.34" spread="2.33"/>
                    <measurement group_id="O8" value="6.09" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>12.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.39</ci_lower_limit>
            <ci_upper_limit>17.27</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>14.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.93</ci_lower_limit>
            <ci_upper_limit>19.30</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>15.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.12</ci_lower_limit>
            <ci_upper_limit>20.60</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>9.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.67</ci_lower_limit>
            <ci_upper_limit>13.62</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.59" spread="2.58"/>
                    <measurement group_id="O2" value="-0.40" spread="2.47"/>
                    <measurement group_id="O3" value="8.88" spread="2.62"/>
                    <measurement group_id="O4" value="14.80" spread="2.39"/>
                    <measurement group_id="O5" value="-3.57" spread="2.59"/>
                    <measurement group_id="O6" value="-2.36" spread="2.38"/>
                    <measurement group_id="O7" value="13.28" spread="2.58"/>
                    <measurement group_id="O8" value="7.84" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>13.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.40</ci_lower_limit>
            <ci_upper_limit>19.53</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>15.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.87</ci_lower_limit>
            <ci_upper_limit>20.52</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>16.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.74</ci_lower_limit>
            <ci_upper_limit>22.95</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>10.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.85</ci_lower_limit>
            <ci_upper_limit>15.55</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="5.52"/>
                    <measurement group_id="O2" value="3.10" spread="5.12"/>
                    <measurement group_id="O3" value="-25.29" spread="5.65"/>
                    <measurement group_id="O4" value="-19.55" spread="4.95"/>
                    <measurement group_id="O5" value="-1.32" spread="4.32"/>
                    <measurement group_id="O6" value="9.96" spread="5.57"/>
                    <measurement group_id="O7" value="-19.41" spread="4.31"/>
                    <measurement group_id="O8" value="-17.20" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.37</ci_lower_limit>
            <ci_upper_limit>-16.34</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-22.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.91</ci_lower_limit>
            <ci_upper_limit>-12.39</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-18.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.40</ci_lower_limit>
            <ci_upper_limit>-8.77</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.31</ci_lower_limit>
            <ci_upper_limit>-15.01</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in VLDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Placebo Q2W</title>
            <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A5 Placebo QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A5 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A5 Evolocumab QM</title>
            <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A20 Placebo Q2W</title>
            <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A20 Placebo QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A20 Evolocumab Q2W</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A20 Evolocumab QM</title>
            <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in VLDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="6.22"/>
                    <measurement group_id="O2" value="2.92" spread="5.45"/>
                    <measurement group_id="O3" value="-24.33" spread="6.34"/>
                    <measurement group_id="O4" value="-17.89" spread="5.27"/>
                    <measurement group_id="O5" value="-3.03" spread="4.70"/>
                    <measurement group_id="O6" value="9.17" spread="5.63"/>
                    <measurement group_id="O7" value="-18.08" spread="4.68"/>
                    <measurement group_id="O8" value="-15.18" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.48</ci_lower_limit>
            <ci_upper_limit>-14.36</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.29</ci_lower_limit>
            <ci_upper_limit>-9.33</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-15.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.72</ci_lower_limit>
            <ci_upper_limit>-4.39</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-24.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.70</ci_lower_limit>
            <ci_upper_limit>-11.99</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of blinded investigational product until the end of the study (up to 14 weeks).</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>A5 Placebo Q2W</title>
          <description>Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>A5 Placebo QM</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>A5 Evolocumab Q2W</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>A5 Evolocumab QM</title>
          <description>Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>A20 Placebo Q2W</title>
          <description>Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>A20 Placebo QM</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>A20 Evolocumab Q2W</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>A20 Evolocumab QM</title>
          <description>Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

